Compare Endeavour Silver Corp (EXK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Twist Bioscience Corp — how do they compare? Endeavour Silver Corp trades at $7.45 (market cap $2.36B), while Twist Bioscience Corp trades at $90.07 (market cap $5.76B). The key difference: Twist Bioscience Corp is far larger — about 2.4× Endeavour Silver Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | TWST | |
|---|---|---|
Market Cap | $2.36B | $5.76B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $102.88 |
52-Week Low | $4.96 | $24.16 |
Enterprise Value | $2.36B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $7.47, down 7.55% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 production of 3.4 million silver equivalent ounces and beat Q1 2026 earnings estimates with $0.21 EPS versus $0.10 expected. Despite negative net income margins and ROE, revenue growth is projected to improve from $468M in 2025 to $614M in 2026. Analyst sentiment remains positive with 78.57% buy ratings.
The outlook is mixed: operational momentum and silver price trends offer upside, but profitability challenges and high valuation ratios pose risks. Investors should weigh strong production growth against persistent negative earnings and cash flow concerns in a volatile commodity market.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
